Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Status:
Terminated
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic
radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a
year.